Chemcon Speciality Chemicals Limited — PPTs, 19-05-2025: Investor Presentation

1. Financial Highlights:

Chemcon Speciality Chemicals reported FY25 revenue of Rs. 207.4 Cr, down 22% YoY due to weak demand and supply disruptions. EBITDA grew 22% to Rs. 32.9 Cr and PAT rose 27% to Rs. 24.5 Cr, reflecting better margin control and operational efficiency. Q4 revenues dipped 8% to Rs. 54.9 Cr, but PAT increased 36% to Rs. 3.9 Cr with margin expansion. Exports contributed 37%, with organic chemicals forming 63% of revenue. The balance sheet shows a stable asset base with Rs. 500.7 Cr equity and low borrowings at Rs. 24.5 Cr. Healthy operating cash flow of Rs. 40.5 Cr supports upcoming investments.

2. Strategic Initiatives & Growth Drivers:

Two new plants (P-10 and P-11) focusing on organic chemicals are slated for commissioning in H1 FY26 to diversify and de-risk the portfolio. Product expansion targets import substitution in India, supported by ongoing process improvements to enhance raw material usage and cost competitiveness. New launches align with pharma and agrochemical sector demands, positioning the company for future growth.

3. Business Developments:

Product introductions like 2 Bromo and Bromobenzene are advancing through client approvals and trials. Engagement with pharmaceutical and agrochemical customers remains strong while the product pipeline broadens to deepen market penetration. No new acquisitions or partnerships reported.

4. Market Position & Competitive Advantage:

Chemcon is India’s only manufacturer of HMDS and Zinc Bromide, leading global producer of CMIC, and top player in calcium bromide. Its scale, multi-plant operations, and strong pharma-related customer relationships create a solid moat. In-house R&D and certifications underpin product quality and innovation.

5. Investor Implications:

Capacity additions and product launches targeting import substitution offer clear positive growth potential. Margin gains despite volume challenges highlight operational strength. Execution risks stem from commissioning schedules and product approvals. Investors should monitor demand recovery in pharma/agro sectors and diversification progress in organics.